Catherine Bakari

Catherine Bakari

Auto-generated profile, based on publicly available information

Catherine Bakari

National Institute for Medical Research, Dar es Salaam, Tanzania

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2023 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
ZPZachary Popkin-Hall
Zachary Popkin-Hall
MSMisago Seth
Misago Seth
RMRashid A Madebe
Rashid A Madebe
RBRule Budodo
Rule Budodo
CBCatherine Bakari
Catherine Bakari
DIDeus S Ishengoma
Deus S Ishengoma
Recent data indicate that non-Plasmodium falciparum species may be more prevalent than thought in sub-Saharan Africa. Although Plasmodium malariae, Plasmodium ovale spp., and Plasmodium vivax are less severe than P. falciparum, treatment and control are more challenging, and their geographic distributions are not well characterized. We randomly selected 3284 of 12 845 samples collected from cross-sectional surveys in 100 health facilities across 10 regions of Mainland Tanzania and performed quantitative real-time PCR to determine presence and parasitemia of each malaria species. P. falciparum was most prevalent, but P. malariae and P. ovale were found in all but 1 region, with high levels (>5%) of P. ovale in 7 regions. The highest P. malariae positivity rate was 4.5% in Mara and 8 regions had positivity rates ≥1%. We only detected 3 P. vivax infections, all in Kilimanjaro. While most nonfalciparum malaria-positive samples were coinfected with P. falciparum, 23.6% (n = 13 of 55) of P. malariae and 14.7% (n = 24 of 163) of P. ovale spp. were monoinfections. P. falciparum remains by far the largest threat, but our data indicate that malaria elimination efforts in Tanzania will require increased surveillance and improved understanding of the biology of nonfalciparum species.

1 February 2024 in medRxiv
Verified
Preprint
Open access
PDF file
DIDeus S. Ishengoma
Deus S. Ishengoma
CMCeline I. Mandara
Celine I. Mandara
CBCatherine Bakari
Catherine Bakari
AFAbebe A. Fola
Abebe A. Fola
RMRashid A. Madebe
Rashid A. Madebe
MWMarian Warsame
Marian Warsame
Background Artemisinin-based combination therapies (ACTs) are the recommended antimalarial drugs for the treatment of uncomplicated malaria. The recent emergence of artemisinin partial resistance (ART-R) in Rwanda, Uganda and Eritrea is of great concern. In Tanzania, a nationwide molecular malaria surveillance in 2021 showed a high prevalence of the Kelch13 (K13) 561H mutation in Plasmodium falciparum from the north-western region, close to the border with Rwanda and Uganda. This study was conducted in 2022 to evaluate the efficacy of artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ) for the treatment of uncomplicated falciparum malaria and to confirm the presence of ART-R in Tanzania. Methods This single-arm study evaluated the efficacy of AL and ASAQ in eligible children aged six months to 10 years at Bukangara Dispensary in Karagwe District, Kagera Region. Clinical and parasitological responses were monitored for 28 days according to standard WHO protocol. Mutations in K13 gene and extended haplotypes with these mutations were analysed using Sanger and whole genome sequencing data, respectively. Findings 176 children (88 in each AL and ASAQ group) were enrolled and all achieved the defined outcomes. PCR-corrected adequate clinical and parasitological response (ACPR) was 98.3% (95% CI: 90.8-100) and 100.0% (95% CI: 95.8-100) for AL and ASAQ, respectively. Parasitaemia on day 3 was observed in 11/88 (12.5%) and 17/88 (19.3%) in the AL and ASAQ groups, respectively. The half-life of parasitaemia was significantly higher (>6.5 hrs) in patients with parasitaemia on day 3 and/or mutations in K13 gene at enrolment. Most patients with parasitaemia on day 3 (8/11 = 72.7% in the AL group and 10/17 = 58.8% in the ASAQ group) had 561H mutation at enrolment. The parasites with K13 mutations were not similar to those from south-east Asia and Rwanda, but had the same core haplotype of a new 561H haplotype reported in Kagera in 2021. Interpretation These findings confirm the presence of ART-R in Tanzania. A context-specific strategy to respond to artemisinin partial resistance is urgently needed. Although both AL and ASAQ showed high efficacy, increased vigilance for reduced efficacy of these ACTs and detection of ART-R in other parts of the country is critical. Funding Bill and Melinda Gates Foundation to the World Health Organization (WHO, OPP 1209843) and the National Institute for Medical Research (NIMR, Inv. No. 002202), and US National Institute for Health (R01AI156267 to JAB, DSI and JJJ, and K24AI134990 to JJJ). Evidence before this study Artemisinin partial resistance (ART-R) is defined as delayed clearance after treatment with an artemisinin combination therapy (ACT) or artesunate monotherapy of a parasite strain carrying a validated marker of ART-R. At present, 13 different Kelch13 (K13) mutations have been validated as markers of ART-R. ART-R is confirmed in an area if a quality-controlled study using an ACT or artesunate monotherapy, finds more than 5% of patients have parasites with validated K13 mutations and delayed clearance as evidenced by either persistent parasitemia detected by microscopy on day 3 or a parasite clearance half-life of ≥5 hours. ART-R was first reported from Cambodia in 2008 and later from several countries in Southeast Asia. Published articles up to December 2023 were searched in PubMed with the terms; “artemisini n”, “artemisinin partial resistance”, “artemisinin-based combination therapies”, “Kelch 13” in combination with “Africa” or “Tanzania”. The publications confirmed the emergence of ART-R associated with mutations in K13: 561H in Rwanda, A675V and C469Y in Uganda and R622I in Eritrea. All these studies showed a high cure rate of the tested ACTs. The R622I mutant was not reported from Southeast Asia but is circulating in the Horn of Africa (Eritrea, Ethiopia, Sudan and Somalia). In Tanzania, a nationwide malaria molecular surveilla nce launched in January 2021 showed a high prevalence of 561H mutation in the north-western region of Kagera, close to the border with Rwanda and Uganda. Added value of this study The study documented delayed parasite clearance associated with pre-treatment validated K13 561H mutation. It confirms and provides evidence for the first-time of ART-R in Kagera region, north-western Tanzania, an area close to the border with Rwanda and Uganda. This makes Tanzania the fourth country in Africa with confirmed ART-R. The study documents presence of K13 mutation associated with ART-R suggesting that partial resistance to artemisinins is rapidly evolving and can still be found in more areas of Africa. Parasites with K13 mutations were not similar to those from south-east Asia and Rwanda, but had the same core haplotype of a new 561H haplotype reported in Kagera in 2021.The findings of this study furthermore show that both AL and ASAQ are highly effective. Implications of all the available evidence The emergence of confirmed ART-R in Africa, so far in four countries (Rwanda, Uganda, Eritrea and Tanzania), poses a serious threat to malaria control in Africa, which accounts for more than 95% of the global malaria burden. The current evidence of ART-R in Kagera region calls for an urgent response, including the development of a context-specific strategy based on the recently launched WHO strategy to respond to antimalarial drug resistance in Africa. The fact that ART-R has been confirmed in Kagera region, an area bordering Rwanda and Uganda, where resistance also has been reported, also calls for cross-border collaboration to harmonize strategies to combat this threat in the Great Lakes region of Africa. Nationwide studies on molecular markers in Tanzania, which revealed a high prevalence of K13 validated mutatio ns in the Kagera region, guided where to conduct the current study. This suggests that molecular marker surveillance could play an important role in conducting targeted antimalarial drug efficacy studies and confirming ART-R in other parts of Tanzania and beyond.

30 December 2023 in medRxiv
Verified
Preprint
Open access
PDF file
ZPZachary Popkin-Hall
Zachary Popkin-Hall
MSMisago Seth
Misago Seth
RMRashid A. Madebe
Rashid A. Madebe
RBRule Budodo
Rule Budodo
CBCatherine Bakari
Catherine Bakari
DIDeus S. Ishengoma
Deus S. Ishengoma
Recent studies point to the need to incorporate non-falciparum species detection into malaria surveillance activities in sub-Saharan Africa, where 95% of malaria cases occur. Although Plasmodium falciparum infection is typically more severe, diagnosis, treatment, and control for P. malariae , P. ovale spp., and P. vivax may be more challenging. The prevalence of these species throughout sub-Saharan Africa is poorly defined. Tanzania has geographically heterogeneous transmission levels but an overall high malaria burden. In order to estimate the prevalence of malaria species in Mainland Tanzania, 1,428 samples were randomly selected from 6,005 asymptomatic isolates collected in cross-sectional community surveys across four regions and analyzed via qPCR to detect each Plasmodium species. P. falciparum was most prevalent, with P. malariae and P. ovale spp. detected at lower prevalence (<5%) in all four regions. P. vivax was not detected. Malaria elimination efforts in Tanzania will need to account for these non-falciparum species.

5 June 2024 in medRxiv
Verified
Preprint
Open access
PDF file
GCGervas A. Chacha
Gervas A. Chacha
FFFilbert Francis
Filbert Francis
SMSalehe S. Mandai
Salehe S. Mandai
MSMisago D. Seth
Misago D. Seth
RMRashid A. Madebe
Rashid A. Madebe
DIDeus S. Ishengoma
Deus S. Ishengoma
Background Malaria is still a leading public health problem in Tanzania despite the implementation of effective interventions for the past two decades. Currently, the country experiences heterogeneous transmission and a higher malaria burden in some vulnerable groups, threatening the prospects for elimination by 2030. This study assessed the prevalence and drivers of malaria infections among asymptomatic individuals in selected communities from five districts within five regions with varying endemicity in Mainland Tanzania. Methods A community cross-sectional survey was conducted in selected communities (covering 15 villages) from five districts, one each from five regions of Kagera, Kigoma, Njombe, Ruvuma, and Tanga from July to August 2023. Asymptomatic participants aged ≥6 months were recruited and tested with rapid diagnostic tests (RDTs) to detect malaria parasites. Demographic, anthropometric, clinical, parasitological, housing type, and socio-economic status (SES) data were captured using questionnaires configured and installed on Open Data Kit (ODK) software run on tablets. The association between parasite prevalence and potential drivers of malaria infections among asymptomatic individuals were determined by univariate and multivariate logistic regression, and the results were presented as crude (cOR) and adjusted odds ratios (aOR), with 95% confidence intervals (CI). Results Testing involved 10,228 individuals and 3,515 (34.4%) had RDT positive results. The prevalence varied from 21.6% in Tanga to 44.4% in Kagera, and ranged from 14.4% to 68.5% in the different villages, with significant differences among regions and villages (p<0.001). The prevalence and odds of malaria infections were significantly higher in males (aOR =1.32, 95% CI:1.19 -1.48, p<0.01), under-fives (aOR = 2.02, 95% CI: 1.74 - 2.40, p<0.01), school children [aged 5 – <10 years (aOR =3.23 95% CI: 1.19–1.48, p<0.01) and 10–15 years (aOR = 3.53, 95% CI: 3.03 – 4.11, p<0.01)], and among individuals who were not using bed nets (aOR = 1.49, 95% CI: 1.29 –1.72, p<0.01). The odds of malaria infections were also higher in individuals from households with low SES (aOR = 1.40, 95% CI:1.16 – 1.69, p<0.001), living in houses with open windows (aOR = 1.24, 95% CI: 1.06 – 1.45, p<0.01) and holes on the wall (aOR = 1.43, 95%CI 1.14 – 1.81, p<0.01). Conclusion There was a high and varying prevalence of malaria infections in the surveyed regions/villages. The odds of malaria infections were higher in males, school children, individuals who did not use bed nets, and participants with low SES or living in poorly constructed houses (with open windows and holes on walls). These findings provide useful information for identifying high-priority vulnerable groups and areas for implementing targeted malaria control interventions for reducing the burden of asymptomatic infections.

20 September 2023 in medRxiv
Verified
Preprint
Open access
PDF file
ZPZachary Popkin-Hall
Zachary Popkin-Hall
MSMisago Seth
Misago Seth
RMRashid A. Madebe
Rashid A. Madebe
RBRule Budodo
Rule Budodo
CBCatherine Bakari
Catherine Bakari
DIDeus S. Ishengoma
Deus S. Ishengoma
Recent data indicate that non- Plasmodium falciparum species may be more prevalent than previously realized in sub-Saharan Africa, the region where 95% of the world’s malaria cases occur. Although Plasmodium malariae, Plasmodium ovale spp., and Plasmodium vivax are generally less severe than P. falciparum , treatment and control are more challenging, and their geographic distributions are not well characterized. In order to characterize the distribution of malaria species in Mainland Tanzania (which has a high burden and geographically heterogeneous transmission levels), we randomly selected 3,284 samples from 12,845 samples to determine presence and parasitemia of different malaria species. The samples were collected from cross-sectional surveys in 100 health facilities across ten regions and analyzed via quantitative real-time PCR to characterize regional positivity rates for each species. P. falciparum was most prevalent, but P. malariae and P. ovale were found in all regions except Dar es Salaam, with high levels (>5%) of P. ovale in seven regions (70%). The highest positivity rate of P. malariae was 4.5% in Mara region and eight regions (80%) had positivity rates ≥1%. We also detected three P. vivax infections in the very low-transmission Kilimanjaro region. While most samples that tested positive for non-falciparum malaria were co-infected with P. falciparum , 23.6% (n = 13/55) of P. malariae and 14.7% (n = 24/163) of P. ovale spp. samples were mono-infections. P. falciparum remains by far the largest threat, but our data indicate that malaria elimination efforts in Tanzania will require increased surveillance and improved understanding of the biology of non-falciparum species.

21 October 2024 in medRxiv
Verified
Preprint
Open access
PDF file
MSMisago Seth
Misago Seth
ZPZachary R. Popkin-Hall
Zachary R. Popkin-Hall
RMRashid A. Madebe
Rashid A. Madebe
RBRule Budodo
Rule Budodo
CBCatherine Bakari
Catherine Bakari
DIDeus S. Ishengoma
Deus S. Ishengoma
Background: Subpatent Plasmodium falciparum infections, defined as infections with parasitaemia density below the detection limit of routine malaria diagnostic tests, contribute to infectious reservoirs, sustain transmission, and cause the failure of elimination strategies in target areas. This study assessed the prevalence of and factors associated with subpatent P. falciparum infections in 14 regions of Mainland Tanzania with varying endemicity. Methods: The study used samples randomly selected from RDT-negative dried blood spots (DBS) (n = 2,685/10,121) collected in 2021 at 100 health facilities across 10 regions of Mainland Tanzania, and four communities in four additional regions. The regions were selected from four transmission strata; high (five regions), moderate (three), low (three), and very low (three regions). DNA was extracted by Tween-Chelex method, and the Pf18S rRNA gene was amplified by quantitative polymerase chain reaction (qPCR). Logistic regression analysis was used to assess the associations between age groups, sex, fever status, and transmission strata with of subpatent infections status, while linear regression analysis was used to assess the association between these factors and subpatent parasite density. Results: Of the selected samples, 525/2,685 (19.6%) were positive by qPCR for P. falciparum , and the positivity rates varied across different regions (range: 4.8 to 39.6%). Under-fives (aOR: 1.4, 95% CI 1.04-1.88; p<0.05) from health facilities had higher odds of subpatent infections compared to other groups, while those from community surveys (aOR: 0.33, 95% CI 0.15-0.72; p = 0.005) had lower odds. Participants from very low transmission stratum had significantly lower odds of subpatent infection compared to those from high transmission straum (aOR=0.53, 95% CI=0.37-0.78; p < 0.01). The log-transformed median parasite density (interquartile range) was 6.9 (5.8 - 8.5) parasites/µL, with significantly higher parasitaemia in the low transmission stratum compared to very low (11.4 vs 7.0 parasites/µL, p<0.001). Conclusion: Even in very low transmission settings, the prevalence of subpatent infections was 13%, and in low transmission settings it was even higher at 29.4%, suggesting a substantial reservoir which is likely to be missed by routine malaria case management strategies. Thus, control and elimination programmes may benefit from adoption of more sensitive detection methods to ensure that a higher proportion of subpatent infections are detected.